Swiss pharmaceuticals giant Novartis posted Thursday a 29 percent increase in first-half net income, at $7.6 billion -- and unveiled its new chief financial officer.The Basel-based firm's net sales ...

For the second quarter, Entresto sales climbed 22% at constant currency to $2.36 billion, contributing to a 11% increase for the group as a whole to $14.05 billion. Novartis cited Kisqali and Entresto ...

The pharmaceutical company raised its full-year profit guidance after continued demand for key drugs fueled growth in ...

Investing.com -- Novartis (LON: 0QLR) (SIX: NOVN) on Thursday posted a 24% rise in second-quarter net income to $4 billion, as sales of key therapies including Kisqali and Entresto drove performance ...

Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...

TSMC, which manufactures advanced semiconductors for clients including Nvidia ( NVDA) and Apple ( AAPL ), said it expects third-quarter revenue to reach between $31.8bn (£23.7bn) and $33bn, a 38% ...